PHARMACY

CDC’s flu recommendations emphasizes convenience of retail pharmacy

BY Michael Johnsen

WHAT IT MEANS AND WHY IT’S IMPORTANT It’s important for three reasons. First, the government is making a strong push for people to get their flu shots — both seasonal and H1N1. Second, that H1N1 flu shot is widely available at your local retail pharmacy. And third, this will further help establish retail pharmacy as the convenient go-to source for health.

(THE NEWS: CDC still urges H1N1 vaccination efforts despite incidence drop. For the full story, click here)

And all of that is good for business, both short term and long term.

Short term, because all of this government messaging that will likely be covered extensively during the evening and late-night newscasts is going to drive traffic into the pharmacy for the flu shot. After all, pharmacy is convenient, and according to the CDC, the vaccine ought to be readily accessible. Because of that messaging, traffic may become heavier than in years past as incidence of the seasonal flu begins picking up later this month or in February, as is expected, a factor that will serve as a sort of “You see? We told you the flu was coming back” call to action for consumers.

Long term, because it’s just one more example of all of the comprehensive services you can find at your local pharmacy, which grow even more comprehensive when you couple that pharmacy with a retail clinic partner. It’s convenient. Pharmacists and nurse practitioners work around their customer’s schedules, not the other way around. And it’s one-stop health shopping for all your needs — you can get the flu shot, cough and cold medicines or immunity boosting supplements and become educated around colds and flu all in one place.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Walgreens offering free review sessions to Medicare Part D beneficiaries

BY Allison Cerra

DEERFIELD, Ill. Walgreens now is offering free review sessions to Medicare Part D beneficiaries at all of its more than 7,100 pharmacies throughout the country.

Following the open enrollment period for Medicare Part D insurance plans, Walgreens is assisting those beneficiaries who’ve made changes to their prescription drug coverage. Review sessions with Walgreens pharmacists are available daily by appointment through Jan. 31, and are designed to help patients maximize their plan benefits.

Review sessions include:

  • A review of beneficiary’s current medications, tiers within their selected plan, co-pays and cost-savings opportunities
  • Discussion of available health and wellness services including pneumonia and shingles vaccinations and 90-day prescription benefits
  • Checks for potential drug interactions

Customers can call their nearest Walgreens pharmacy to schedule an appointment. Visit www.walgreens.com or call 1-800-Walgreens for store locations and hours.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Watson files FDA application for generic LoSeasonique

BY Allison Cerra

MORRISTOWN, N.J. Watson Labs, a subsidiary of specialty pharmaceutical company Watson Pharmaceuticals, has filed an abbreviated new drug application to the Food and Drug Administration for an oral contraceptive.

Watson is seeking approval to market its levonorgestrel and ethinyl estradiol (0.10-mg/0.02-mg) oral contraceptive product prior to the expiration of U.S. Patent No. 7,615,545, which is owned by Duramed Pharmaceuticals, a subsidiary of Teva.  Watson’s levonorgestrel and ethinyl estradiol product is a generic version of Teva’s LoSeasonique, which is indicated for the prevention of pregnancy.

On Nov. 23, 2009, pursuant to the Hatch-Waxman Act, Watson notified Duramed that its ANDA requesting approval from the FDA for a generic version of LoSeasonique contained a paragraph IV certification asserting that the LoSeasonique patent is invalid, unenforceable and/or not infringed.  Teva Women’s Health filed suit against Watson on Jan. 6, 2010 in the U.S. District Court for the District of New Jersey seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent No. 7,615,545.  Based on available information, Watson believes it may be entitled to 180 days of generic market exclusivity or shared exclusivity should its product receive approval.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES